Withings has acquired Biosency, a French startup that builds remote monitoring tools for patients with respiratory diseases. The deal, announced June 22, 2026, brings Withings into respiratory care for the first time and adds a clinically validated COPD detection algorithm to its existing suite of connected health products.
Biosency was founded in 2017 in Rennes and spent nearly a decade building its technology inside the French healthcare system. Its core product is a modular monitoring platform for patients with respiratory insufficiency, and its standout feature is a medically certified algorithm that can detect COPD exacerbations early, before symptoms become severe enough to require emergency care. Early detection of COPD flare-ups is a well-documented challenge in chronic disease management, and automated remote tools are increasingly seen as one of the more practical solutions at scale.
For Withings, the move fits a broader strategy. The company already tracks over 90 biomarkers through its consumer and clinical devices, used by more than 15 million people worldwide. Withings president Eric Carreel pointed to a direct connection between respiratory monitoring and the cardiometabolic disease work his team is already doing, noting that the two areas share similar patterns of risk detection and early intervention.
What Biosency actually built
The Biosency platform is designed for patients living with chronic respiratory conditions and the clinicians who manage them. Its key components include:
- A modular remote monitoring solution for respiratory insufficiency
- A certified algorithm for early detection of COPD exacerbations
- Established clinical research partnerships within the French healthcare system
- A regulatory certification already in place, which avoids the need to restart approval processes
That last point matters more than it might seem. Medical software certification in Europe is a slow, expensive process. Withings is acquiring a tool that is already cleared for use, not a research project that still needs years of regulatory work.
What changes and what stays the same
The Biosency team is staying in Rennes and continuing to develop the product from there. Withings says it will maintain full continuity of the solution, its certification, and its support for both patients and healthcare professionals. Biosency CEO Marie Pirotais said the deal will let her team accelerate deployment without abandoning the company’s original goals.
In practical terms, Biosency gains access to Withings’ manufacturing scale, distribution network, and engineering resources. In return, Withings gets a foothold in respiratory care and a clinical team with genuine COPD expertise, which is not easy to build from scratch.
The bigger picture for European connected health
Withings has been explicit about wanting to build a strong, independent European player in connected health. That framing is deliberate. European health tech has historically struggled to compete with US and Asian giants at scale, and several European digital health companies have either been acquired by American firms or failed to grow beyond their home markets.
This acquisition, though modest in scope, follows the logic of building depth rather than just breadth. Withings already covers cardiovascular metrics, sleep, weight, and blood pressure through its consumer devices. Adding respiratory monitoring through a clinically grounded acquisition, rather than a rushed product launch, is a more credible path into hospital and clinic partnerships.
The French healthcare system, where Biosency already has an established presence, also gives Withings a ready market to test and scale the respiratory platform before expanding elsewhere in Europe.
Why this matters beyond the deal itself
Remote patient monitoring is one of the faster-growing areas in healthcare technology right now. Health systems across Europe and North America are under pressure to manage more patients with fewer in-person visits, and chronic respiratory diseases like COPD are among the most expensive conditions to manage when patients end up in emergency care.
Tools that can flag deterioration early, and route that signal to a clinician before a crisis develops, have real economic value to hospitals and insurers. Biosency’s algorithm is aimed exactly at that problem. Whether Withings can distribute it at meaningful scale, and integrate it with the rest of its health monitoring ecosystem, is the question worth watching over the next two to three years.
More information is available at withings.com.